burlington-massachusetts
(3)
PAQ Therapeutics
PAQ Therapeutics is a clinical-stage biotechnology company in Burlington, Massachusetts developing a new class of small-molecule degraders that harness autophagy, the body's natural cellular recycling system, to destroy disease-causing proteins. Its proprietary ATTEC (autophagosome-tethering compound) platform aims to eliminate targets that traditional inhibitors cannot reach. The company's lead programs are KRAS degraders - PT0253, a selective KRAS G12D degrader, and PT0511, a pan-KRAS degrader - both in Phase 1 clinical trials for lung, colorectal and pancreatic cancers driven by KRAS mutations.
Deborah Theobald
Deborah Theobald is the co-founder and CEO of b Inc. (formerly Vecna Technologies), a Burlington, Massachusetts company building telepresence robots and automation for healthcare, education, government, and tourism. An MIT-trained aerospace engineer with a master's in space robotics, she has spent more than two decades turning research-grade robotics into tools that help people connect and get care. She also founded VecnaCares, a charitable venture deploying health-record technology in low-resource settings across Africa, Haiti, and beyond. Her guiding belief: technology should serve humanity, not overshadow it.
b Inc.
b Inc. (formerly Vecna) is a Burlington, Massachusetts technology company founded in 1998 by MIT engineers Deborah and Daniel Theobald. It builds automation and telepresence technology that keeps human connection at the center of healthcare, education, government, and tourism - from patient self-service kiosks and intake software used across U.S. hospitals to VGo telepresence robots that let people be present from anywhere. Its guiding belief: technology should serve humanity, not overshadow it.